Impacts of ACE insertion/deletion variant on cardiometabolic risk factors, premature coronary artery disease, and severity of coronary lesions.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Peptidyl-Dipeptidase A*/genetics ; Coronary Artery Disease*/genetics ; INDEL Mutation* ; Cardiometabolic Risk Factors*; Humans ; Male ; Female ; Blood Pressure ; Genetic Predisposition to Disease ; Severity of Illness Index ; Middle Aged ; Genotype ; Body Mass Index ; Risk Factors ; Triglycerides/blood ; Adult

Angiotensin-converting enzyme (ACE) is closely related to cardiometabolic risk factors and atherosclerosis. This study aims to investigate whether the insertion/deletion (I/D) variant of ACE gene impacts cardiometabolic risk factors, premature coronary artery disease (PCAD), and severity of coronary lesions. PubMed, Cochrane Library, Central, CINAHL, and ClinicalTrials.gov were searched until December 22, 2023. 94,270 individuals were included for the analysis. Carriers of DD genotype had higher levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), and waist circumference (WC) than carriers of II or ID genotypes. In addition, carriers of DD genotype were at high risk of PCAD and multiple vessel lesions. The impacts of ACE I/D variant on lipid levels were significant in American individuals but stronger in male individuals. In contrast, the impacts of ACE I/D variant on PCAD and severity of coronary lesions were primarily significant in Caucasian individuals. This study indicates that the ACE I/D variant has a slight but significant impact on cardiometabolic risk factors, PCAD, and severity of coronary lesions. Angiotensin-converting enzyme inhibitors (ACEI) may benefit high-risk populations with ACE DD genotype to prevent PCAD and multiple vessel lesions.PROSPERO registration number: CRD42023426732.
(© 2024. The Author(s).)

Nitric Oxide. 2001 Aug;5(4):343-8. (PMID: 11485372)
Gene. 2012 May 1;498(2):270-5. (PMID: 22387727)
Am J Hum Genet. 1992 Jul;51(1):197-205. (PMID: 1319114)
J Am Coll Cardiol. 2022 Mar 1;79(8):819-836. (PMID: 35210038)
Circulation. 1995 Sep 15;92(6):1387-8. (PMID: 7664416)
Ann Intern Med. 1993 Feb 15;118(4):246-54. (PMID: 8420442)
Rev Assoc Med Bras (1992). 2019 Jul 22;65(6):923-929. (PMID: 31340327)
Scand J Clin Lab Invest. 1997 Apr;57(2):127-32. (PMID: 9200271)
Nucleic Acids Res. 1992 Mar 25;20(6):1433. (PMID: 1313972)
Atherosclerosis. 1998 Jul;139(1):153-9. (PMID: 9699903)
Biomolecules. 2021 Jul 15;11(7):. (PMID: 34356659)
Cardiovasc Diabetol. 2022 Sep 16;21(1):187. (PMID: 36114495)
J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):844-50. (PMID: 26195267)
Circulation. 2002 Dec 17;106(25):3143-421. (PMID: 12485966)
Clin Chim Acta. 2005 Jan;351(1-2):87-94. (PMID: 15563875)
Circulation. 2019 Jun 18;139(25):e1082-e1143. (PMID: 30586774)
J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):296-304. (PMID: 22277253)
J Cardiovasc Pharmacol. 1994 Oct;24(4):670-7. (PMID: 7528851)
Diabetes. 2007 Mar;56(3):863-71. (PMID: 17327458)
Eur Heart J. 2003 Feb;24(3):249-57. (PMID: 12590902)
BMJ. 2009 Jul 21;339:b2700. (PMID: 19622552)
Nature. 1992 Oct 15;359(6396):641-4. (PMID: 1328889)
Eur Heart J. 2008 Jun;29(11):1370-6. (PMID: 18413308)
J Clin Invest. 1990 Oct;86(4):1343-6. (PMID: 1976655)
Contemp Clin Trials. 2007 Feb;28(2):105-14. (PMID: 16807131)
Clin Chem Lab Med. 2008;46(4):446-52. (PMID: 18298340)
Cardiology. 2002;97(1):29-36. (PMID: 11893827)
Ann Intern Med. 2008 Jan 1;148(1):16-29. (PMID: 17984484)
Biometrics. 1994 Dec;50(4):1088-101. (PMID: 7786990)
Hypertens Res. 2002 Nov;25(6):875-80. (PMID: 12484511)
N Engl J Med. 1989 Sep 28;321(13):868-73. (PMID: 2671740)
J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):478-86. (PMID: 22679279)
Indian J Med Res. 2016 Jun;143(6):748-755. (PMID: 27748299)
Hum Genet. 1994 Aug;94(2):189-92. (PMID: 7913911)
Eur Heart J. 2010 Aug;31(15):1854-64. (PMID: 20538738)
Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2090-6. (PMID: 14525797)
Ann Intern Med. 1996 Jul 1;125(1):19-25. (PMID: 8644984)
BMC Cardiovasc Disord. 2023 May 16;23(1):254. (PMID: 37193968)
Am J Med Genet C Semin Med Genet. 2017 Sep;175(3):343-353. (PMID: 28834162)
Front Cardiovasc Med. 2023 May 03;10:1091612. (PMID: 37206099)
Hypertension. 1992 Oct;20(4):473-7. (PMID: 1398882)
Metabolism. 1998 May;47(5):622-6. (PMID: 9591757)
J Clin Invest. 1993 Apr;91(4):1453-8. (PMID: 8473494)
Clin Biochem. 2010 Oct;43(15):1189-94. (PMID: 20655894)
Eur Heart J. 2020 Jan 1;41(1):111-188. (PMID: 31504418)

Keywords: Angiotensin-converting enzyme; Cardiometabolic risk factors; Multiple vessel lesions; Premature coronary artery disease

EC 3.4.15.1 (Peptidyl-Dipeptidase A)
EC 3.4.15.1 (ACE protein, human)
0 (Triglycerides)

Date Created: 20240607 Date Completed: 20240607 Latest Revision: 20240611

20240611

PMC11161653

10.1038/s41598-024-64003-w

38849492